Antibodies

10 Feb 2020 Bayer announces Phase III trials with new aflibercept 8mg formulation
10 Feb 2020 Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study
09 Feb 2020 EYLEA® (aflibercept) Injection Reduced Risk of Developing Vision-Threatening Events by 75% After Two Years in Patients with Diabetic Retinopathy
07 Feb 2020 Aduro Biotech Announces Milestone Achieved under Merck Collaboration for Initiation of Phase 2 Trial of Anti-CD27 Agonist MK-5890 in Non-Small Cell Lung Cancer
06 Feb 2020 Scholar Rock Presents Data for SRK-015 at the SMA Europe 2nd International Scientific Congress
06 Feb 2020 Jounce Therapeutics Presents New Vopratelimab Predictive Biomarker Data Supporting Use in the Upcoming SELECT Trial at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Annual Meeting and Announces Research Collaboration with NanoString Technologies
06 Feb 2020 Kleo Pharmaceuticals Receives IND Authorization to Proceed from FDA for its Multiple Myeloma Therapeutic
06 Feb 2020 CytoDyn Files a Phase 2 Basket Trial with Leronlimab (PRO 140) for Treatment of All Solid Tumor Cancers
04 Feb 2020 Navrogen and Levena Announce Collaboration to Develop Antibody Drug Conjugates (ADCs) to Treat Humoral Immuno-Suppressed Cancers
04 Feb 2020 Regeneron Announces Expanded Collaboration with HHS to Develop Antibody Treatments for New Coronavirus
03 Feb 2020 GSK announces European Medicines Agency (EMA) accepted marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma
03 Feb 2020 United Therapeutics Announces Study of Unituxin® (dinutuximab) for Small Cell Lung Cancer Did Not Meet Primary Endpoint
02 Feb 2020 Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab)
02 Feb 2020 Bristol-Myers Squibb Withdraws European Application of Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
30 Jan 2020 F-star Therapeutics Announces FDA Acceptance of IND Application for FS120
28 Jan 2020 FDA Accepts for Priority Review Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
28 Jan 2020 Avacta’s Proprietary TMAC Cancer Therapy Platform Demonstrates Successful Proof-of-Concept in Pre-Clinical Study
28 Jan 2020 Leronlimab Under Evaluation for Potential Treatment of Coronavirus
28 Jan 2020 WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus
28 Jan 2020 AbCellera Is Mobilizing a Response to the Novel Coronavirus Outbreak as Part of Its DARPA P3 Program
28 Jan 2020 Surface Oncology Announces FDA Clearance of SRF617 and SRF388 INDs to Initiate Phase 1 Clinical Trials
28 Jan 2020 Acceleron Announces Sotatercept Achieved Primary and Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Patients with Pulmonary Arterial Hypertension
27 Jan 2020 AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer
27 Jan 2020 Genentech Submits Supplemental Biologics License Application to the FDA for Tecentriq in Combination With Avastin for the Most Common Form of Liver Cancer
27 Jan 2020 AstraZeneca to recover the global rights to brazikumab (MEDI2070) from Allergan

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top